# Inhibrx Biosciences, Inc. (INBX)

> Source: Nexqual · https://nexqual.com/INBX · data as of 2026-10-22 20:00 UTC · cite as "Nexqual, Inhibrx Biosciences, Inc. (INBX), nexqual.com/INBX" · informational, not investment advice.

**Price:** USD 97.1 (-1.11% on the day) · last close of Oct 22, 2026; US market pre market, not a live price. Prev close 98.19 · day 94.04–100.2 · 52w 28.16–155.29 · market cap $1.43B · NMS

## Key facts
- 1 of 80 tracked superinvestors hold INBX (13F, Q2 2026): 0 new, 0 added, 1 reduced, 0 unchanged.
- Insider open-market sales, last ~7 months: 2 Form 4 filings, $279K; 2 not under a Rule 10b5-1 plan ($279K); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Insider open-market purchases, last ~7 months: 7 Form 4 filings, $6.3M; 0 by opportunistic insiders, 0 by routine insiders.
- Total return with dividends: 1Y +242.4% vs S&P 500 +14.9%; 5Y +497.5% vs S&P 500 +80.3%.
- Next earnings: 2026-11-13, EPS estimate USD -2.36, revenue estimate $0K.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|
| Revenue | $1.8M | $200K | $1.3M | — |
| Operating income | -$219M | -$331M | -$135M | -$128M |
| Net income | -$241M | $1.69B | -$140M | -$138M |
| EPS (diluted) | -$20.48 | $112.62 | -$9.04 | — |
| Free cash flow | -$198M | -$197M | -$130M | -$132M |
| Operating margin | -12178.9% | -165724.0% | -10386.5% | — |
| Net margin | -13408.9% | 843786.0% | -10773.5% | — |
| Revenue growth | — | -88.9% | +550.0% | — |
| Cash + short-term investments | $278M | $153M | $124M | — |
| Total debt | $207M | $0K | $101M | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
FCF yield -9.23% · Earnings yield -9.67% · Net debt $42.9M · EV $1.47B
P/E at fiscal year-ends: Dec 2024 0.1x.

## Superinvestors (SEC 13F-HR, Q2 2026)
1 of 80 tracked investors hold INBX. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Viking Global | Viking Global Investors | 0.30% | $106M | Reduced -21.8% |

## Insider sales (SEC Form 4, open-market, last ~7 months)
0 of 2 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-09-11…2026-09-15 | Manhard Kimberly | Director | 1,500 | $164K | 16.7% | No | Too little history (no open-market trades in 2023 or 2025) |
| 2026-09-08…2026-09-09 | Manhard Kimberly | Director | 1,000 | $115K | 10% | No | Too little history (no open-market trades in 2023 or 2025) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

## Insider purchases (SEC Form 4, open-market, last ~7 months)
7 purchases, $6.3M. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.
| Trade date | Insider | Role | Shares | Value | Avg price | Insider type |
|---|---|---|---|---|---|---|
| 2026-10-14 | Lappe Mark | Chief Executive Officer | 10,040 | $849K | 84.56 | Too little history (no open-market trades in 2023 or 2025) |
| 2026-09-25…2026-09-28 | Lappe Mark | Chief Executive Officer | 10,000 | $999K | 99.88 | Too little history (no open-market trades in 2023 or 2025) |
| 2026-09-23 | Kayyem Jon Faiz | Director | 5,000 | $500K | 100 | Too little history (no open-market trades in 2023 or 2025) |
| 2026-09-16 | Kayyem Jon Faiz | Director | 5,000 | $500K | 100 | Too little history (no open-market trades in 2023 or 2025) |
| 2026-09-08 | Kayyem Jon Faiz | Director | 5,000 | $568K | 113.52 | Too little history (no open-market trades in 2023 or 2025) |
| 2026-09-08 | Forsyth Douglas | Director | 2,500 | $287K | 114.65 | Too little history (no open-market trades in 2023 or 2025) |
| 2026-09-08 | Lappe Mark | Chief Executive Officer | 25,000 | $2.6M | 105.82 | Too little history (no open-market trades in 2023 or 2025) |

## Analysts
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-24 | HC Wainwright & Co. | Initiated | Buy | $245 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-23) | 5Y (from 2024-05-27) |
|---|---|---|
| Total return | +242.4% | +497.5% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +243.8% | +110.2% |
| Volatility (annualized) | 103.7% | 72.3% |
| Max drawdown | -44.1% (May 2026→Jul 2026) | -39.3% (May 2026→Jul 2026) |

## Peers (Biotechnology)
LGND (Ligand Pharmaceuticals Incorpor) USD 307.82 -2.21% · RYTM (Rhythm Pharmaceuticals, Inc.) USD 90.9 +2.57% · IOVA (Iovance Biotherapeutics, Inc.) USD 14.14 -3.28% · PRAX (Praxis Precision Medicines, Inc) USD 258.92 +0.96% · IONS (Ionis Pharmaceuticals, Inc.) USD 43.91 -0.81% · ABVX (Abivax SA) USD 90.23 -3.49%

## More
Full page: https://nexqual.com/INBX · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Revenue by product line (quarter ended 2026-06-30)

| Line | Revenue | Share | YoY |
|---|---|---|---|
| Total revenue | $0 | 100% | — |

## Company outlook (8-K filed 2026-08-13)

- "The Company expects to announce interim results from these cohorts during the first quarter of 2027. ◦ In June 2026, the U.S."

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $-2.35 | $-2.39 | -1.5% | $0 | 2 |
| Next quarter (ends 2026-12-31) | $-2.42 | $-2.45 | -1.4% | $0 | 2 |
| Current fiscal year (ends 2026-12-31) | $-9.26 | $-9.26 | -0.1% | $0 | 2 |
| Next fiscal year (ends 2027-12-31) | $-8.76 | $-6.30 | +39.0% | $36.1M | 2 |